Background {#Sec1}
==========

Selenium is a trace element with an important role in antioxidative protection \[[@CR1]--[@CR7]\]. It is a component of selenocysteine incorporated in diverse array of antioxidative selenoenzymes that include glutathione peroxidase and thioredoxin reductase, which reduce the excessive levels of reactive oxygen species (ROS) \[[@CR1], [@CR8]--[@CR11]\]. At present, there are reports on reproductive and pregnancy complications as outcomes of selenium deficiency \[[@CR2], [@CR3], [@CR12], [@CR13]\]. However, there are insufficient evidences about the capability of selenium supplementation in preventing reproductive health and pregnancy disorders \[[@CR11], [@CR12]\]. In fact, there are only limited research trials of selenium supplementation during pregnancy \[[@CR1], [@CR11]\]. More intervention trials are recommended to determine the beneficial effects of selenium to pregnancy outcomes \[[@CR12], [@CR13]\].

One of the identified gaps among studies regarding selenium and reproductive health is optimizing the best timing of supplementation \[[@CR3]\]. This lack of information about selenium is supported by other research studies recommending further investigation on the effects of timing of micronutrient administration on pregnancy outcomes \[[@CR14], [@CR15]\]. Hence, this present study addresses this gap by finding out the best timing of selenium administration during pregnancy, which refers to the different stages of periconception period.

Moreover, to respond with one of the United Nations Millennium Development Goals (MDG), that is, improving pregnancy outcome by optimizing the mother's nutritional status \[[@CR16]\], and to mitigate the alarming state of maternal deaths caused by pregnancy complications, this study aims to assess the effects of maternal Selenium-supplementation at varying stages of periconception period on murine blastocyst morphometric parameters, percent occurrence of good quality blastocysts, and implantation status. It is with hope that maternal selenium supplementation might be considered as one of the possible health measures in improving pregnancy outcome.

Methods {#Sec2}
=======

Chemicals and reagents {#Sec3}
----------------------

Selenium tablets, containing 200 μg of selenium yeast, were bought from one of the General Nutrition Centers (GNC) Live Well Health Stores in Metro Manila, Philippines. All other chemicals and reagents were purchased from other scientific chemical suppliers.

Test animals and maintenance {#Sec4}
----------------------------

Fifty six (56) seven-week old ICR female mice and twenty-eight 15--20 week old ICR male mice, approximately 30.0 g of weight were obtained from the stock bred of the Marine Science Institute -- Natural Products Laboratory, University of the Philippines, Diliman. All mice were kept individually in standard - sized cages in the animal house of Department of Biology at De La Salle University -- Manila, where they were acclimatized for two weeks maintaining at 12 h light: 12 h dark cycle with 28--30 °C ambient temperature. Once a week, all animal cages were sanitized, beddings were autoclaved and replaced, feed plates and water bottles were also washed

An adult mouse of 25.0 to 30.0 g weight consumes 3.0 to 6.0 g of food pellet per day \[[@CR17]\]. Hence, all mice were given 6.0 g of food pellets per day. They had access to purified drinking water *ad libitum*.

The standard basal diet are in the form of food pellets that are available in the local pet markets in the Philippines. This is composed of wheat bran, soybean hull, soybean meal, corn, rice, alfalfa, full fat soybean, and yucca extract. Guaranteed analysis shows that these are composed of 18.0% crude protein, 16.0% crude fiber, 2.5% crude fat, 10.0% moisture, 10.0% ash, 0.9% calcium, and 0.7% phosphorus. Other macro- and micronutrients include the following: fructo-oligosaccharide, vitamin A acetate, vitamin B12 supplement, vitamin D3 supplement, folic acid, biotin, choline chloride, tocopheryl acetate, menadione sodium bisulfate, ascorbic acid, nicotinic acid, calcium-D-panthothenate, riboflavin-5′-phosphate sodium, thiamine hydrochloride, pyridoxine hydrochloride, calcium carbonate, potassium iodide, sodium chloride, monocalcium phosphate, ferrous sulfate, zinc oxide, manganous oxide, and copper sulfate.

The handling and maintenance of laboratory test animals adhered to the Rules, Regulations, and Guiding Principles of the Veterinary Medical Association's safety standards of the Philippines and Philippine Association for Laboratory Animal Science.

The experimental design {#Sec5}
-----------------------

The study consisted of two phases; the assessments of blastocyst morphology (phase I) and implantation status (phase II).

After the acclimatization period, at which time the females were already sexually mature, were then randomly assigned into four groups with 14 members each. Two mice per group were used for phase I and twelve mice per group for phase II.

For the unsupplemented group (Group I), all were given with basal food pellets (6.0 g food pellet/day) without selenium supplement. For the treated groups, the timing for selenium administration were as follows: for the pregestation treatment group (Group II), females were given with basal food pellets + 3.0 μg selenium supplement per day for three weeks only before mating; for the pregestation-to-gestation treatment group (Group III), all were also given with diet similar with that of Group II for three weeks before mating, but females in phase I and phase II were continuously given with similar diet for 4 days and 16 days after mating respectively; for the gestation treatment group (Group IV), all mice were given with diet similar with Group II and III, but females in phase I and phase II were only given with the diet for 4 days and 16 days after mating respectively.

Mating was allowed to take place at the end of the third week (22^nd^ day). Each cage had 1 male with 2 females. To determine pregnancy, the females were checked for the presence of vaginal copulatory plugs from 0700 to 0800 h. Females that were found positive for vaginal plugs were placed in separate cages and their embryos were considered as 0.5 day post coitum (dpc) \[[@CR7]\].

For phase I, embryo retrieval was performed at 4.5 dpc for blastocyst morphology assessment. For phase II, ovaries and uteri samples were obtained at 16.5 dpc for implantation success assessment.

Treatment administration {#Sec6}
------------------------

Selenium supplementation was administered everyday via dietary route. The selenium supplement was prepared by dissolving a 200 μg selenium yeast tablet in 10 mL mineral water to yield 3.0 μg selenium in 0.15 mL solution.

It is the 0.15 ml solution that was coated into 2.0 g food pellets, which was given as initial consumption for the day to ensure that the whole supplement was consumed.

After the initial consumption, the remaining 4.0 g food pellets was supplied in full. The dose of selenium supplement in this study was computed based on the dosage used by Soudani et al. \[[@CR18]\], which is 0.5 mg selenium/kg diet. This selenium dosage was proven to provide protection against oxidative stress and damage in rats.

Phase I: blastocyst morphology assessment {#Sec7}
-----------------------------------------

Two female mice per group were sacrificed by cervical dislocation on 4.5 dpc. Blastocysts were recovered by flushing the uterus with M2 medium under a stereomicroscope. The recovered blastocysts were observed under an inverted microscope (Nikon Eclipse TS100) and were photographed using digital sight camera at 400x and 600x magnification.

The images of blastocysts at 600x magnification were analyzed using the Image J software (Fig. [1](#Fig1){ref-type="fig"}). The morphometric parameters that were measured using 'line and oval selection tools' are as follows: mean embryo diameter (MED), mean zona pellucida diameter (MZPD), embryo area (EA), zona pellucida area (ZPA), embryo perimeter (EP), and zona pellucida perimeter (ZPP) \[[@CR19], [@CR20]\].Fig. 1Photomicrographs of blastocysts (*arrows*) at 600x magnification being measured using the Image J software. **a** Unsupplemented group, **b** Pregestation only group, **c** Pregestation-to-gestation group, **d** Gestation only group

The collected embryos were classified accordingly on stages of development based on the Manual of the International Embryo Transfer Society (IETS) about 'A procedural guide and general information for the use of embryo transfer technology emphasizing sanitary procedures' \[[@CR21]\]. Since all embryos were collected on 4.5 dpc, these were classified into three categories that were described as follows: compact morula with early cavitation (stage 4); early blastocyst (stage 5) described with the presence of blastocoele occupying less than half of the embryo; mid-blastocyst (stage 6) described with the presence of blastocoele occupying more than half or entirely fills the embryo \[[@CR22], [@CR23]\].

Blastocyst quality was scored and evaluated based also on the guidelines of the IETS Manual. The three classifications of blastocyst quality were excellent or good (score 1), fair (score 2), and poor (score 3) \[[@CR21], [@CR24]\]. The descriptions in each classification were determined through thresholding or binary contrast enhancement using Image J software on embryo images taken at 400x magnification.

Phase II: implantation status assessment {#Sec8}
----------------------------------------

On 16.5 dpc, twelve females per group were sacrificed by cervical dislocation. Uteri and ovaries were obtained, and were assessed for the number of implantations, foetuses, and corpora lutea.

Ovaries were fixed in 10% buffered formalin overnight and were brought to the Philippine Kidney Dialysis Foundation for standard histological preparations using hematoxylin and eosin stain. Ovaries were observed under an inverted microscope (Nikon Eclipse TS100) to determine the number of corpora lutea. The percent pre-implantation loss per female was calculated using this formula \[[@CR25]--[@CR27]\].$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
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Implantation sites were assessed by immersing the uteri into 2% sodium hydroxide (NaOH) solution until the sites become visible and clear. Implants were classified as follows: viable fetuses have distinct fetal capsule and placenta \[[@CR28]\]; non-viable fetuses are underdeveloped and smaller than viable fetuses \[[@CR27], [@CR29]\] with identifiable ischemia or hemorrhage \[[@CR28]\]; and resorptions or resorbed embryos described as small, round, black or dark brown masses, which are signs of necrosis \[[@CR29]\]. Percent post--implantation loss per female was determined using this formula \[[@CR27], [@CR29]\].$$\documentclass[12pt]{minimal}
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Statistical analysis {#Sec9}
--------------------

Statistical differences of data on blastocyst morphology among groups were analyzed by one-way analysis of variance (ANOVA) followed by post-hoc Tukey HSD test. Blastocysts were classified or scored based only on qualitative assessment. Percent pre- and post-implantation losses were analyzed using non-parametric Kruskal-Wallis test, and Mann Whitney test to determine the specific pairs of experimental groups with significant differences. Data were presented as mean ± SEM (standard error of the mean). All statistical tests were conducted using Statistical Package for the Social Sciences (SPSS) Version 22. Effects of the treatment were considered significant at *P-values \< 0.05*.

Results {#Sec10}
=======

General observations {#Sec11}
--------------------

Three developmental stages of blastocysts were identified in the study. These were stage 4, characterized as compact morula with cavitation; stage 5, characterized as early blastocyst having blastocoele occupying less than half of the embryo; and stage 6, characterized as mid-blastocyst having blastocoele occupying more than half of the embryo.

Morphometric measurements of blastocysts and occurrence of good quality blastocysts {#Sec12}
-----------------------------------------------------------------------------------

Group III exhibited the lowest values of all the morphometric parameters (Table [1](#Tab1){ref-type="table"}). Most of these parameters were significantly lower than Group I but not from those of treatment Groups II and IV.Table 1Morphometric parameters of mice blastocysts from all groupsGroups*n*Morphometric parametersMean embryo diameter (MED) μmMean zona pellucida diameter (MZPD) μmEmbryo area (EA) μm^2^Zona pellucida area (ZPA) μm^2^Emrbyo perimeter (EP) μmZona pellucida perimeter (ZPP) μmGroup I*12*21.20±0.9325.17±1.07376.18±33.81509.38±41.6368.01±3.1379.31±3.33Group II*15*19.86±0.59^a^22.94±0.61^a^317.94±18.97^a^418.83±21.36^a^62.90±1.71^a^72.30±1.69^a^Group III*13*18.60±0.58^a^21.65±0.54^a\*^275.28±15.02^a\*^376.46±18.32^a\*^58.57±1.65^a\*^68.56±1.72^a\*^Group IV*20*20.21±0.43^a^23.49±0.44^a^301.94±12.41^a\*^422.88±15.13^a^61.39±1.24^a^72.70±1.27^a^Values are given as mean±SEM. *n* = number of blastocystValues with the same letters in the treatment groups within column are not significantly differentValues in the treatment groups with asterisk are significantly different from the unsupplemented groupGroup I (Unsupplemented group), Group II (Pregestation only group), Group III (Pregestation-to-gestation group), and Group IV (Gestation only group)

Percent occurrences of good (Fig. [2](#Fig2){ref-type="fig"}), fair (Fig. [3](#Fig3){ref-type="fig"}), and poor (Fig. [4](#Fig4){ref-type="fig"}) quality blastocysts are shown in Table [2](#Tab2){ref-type="table"}. Group IV showed the highest percent occurrence of good quality blastocysts followed by Group II. Groups I and III were comparably low (Table [2](#Tab2){ref-type="table"}; Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, and [4](#Fig4){ref-type="fig"}).Fig. 2Photomicrographs of good quality blastocysts (*arrows*) at 400x magnification. **a** Unsupplemented group (Group I), **b** Pregestation only group (Group II), **c** Pregestation-to-gestation group (Group III), and **d** Gestation only group (Group IV) Fig. 3Photomicrographs of fair quality blastocysts (*arrows*) at 400x magnification. **a** Unsupplemented group (Group I), **b** Pregestation only group (Group II), and **c** Pregestation-to-gestation group (Group III) Fig. 4Photomicrographs of poor quality blastocysts (*arrows*) at 400x magnification. **a** Unsupplemented group (Group I), **b** Pregestation only group (Group II), **c** Pregestation-to-gestation group (Group III), and **d** Gestation only group (Group IV) Table 2Percent occurrence of three classification of blastocyst quality following the guidelines of the IETS ManualGroups*n*Actual blastocyst count (Percent Occurrence %)Good (1)Fair (2)Poor (3)Group I124 (33.3)6 (50)2 (16.67)Group II1511 (73.3)3 (20)1 (6.7)Group III135 (38.5)4 (30.8)4 (30.8)Group IV2019 (95)01 (5)*n* = number of blastocystPercent in parenthesisGroup I (Unsupplemented group), Group II (Pregestation only group), Group III (Pregestation-to-gestation group), and Group IV (Gestation only group)

Implantation losses {#Sec13}
-------------------

The number of corpora lutea determined through hematoxylin and eosin (H&E) staining of ovaries is shown in Fig. [5](#Fig5){ref-type="fig"} with representative histophotographs that are shown in Fig. [6](#Fig6){ref-type="fig"}. This reproductive outcome among pregnant mice is used to compute for percent pre-implantation loss.Fig. 5Number of corpora lutea obtained from H&E stained ovaries from all groups. Values are given as mean ± SEM. Group I (Unsupplemented group), Group II (Pregestation only group), Group III (Pregestation-to-gestation group), and Group IV (Gestation only group) Fig. 6Histological cross -- sections of ovaries showing the corpora lutea (CL) from all groups at 40x magnification. **a** Unsupplemented group, **b** Pregestation only group, **c** Pregestation-to-gestation group, **d** Gestation only group

Group II significantly exhibited the lowest percent pre-implantation loss followed by Group IV. Both of these groups exhibited significantly lower percent pre-implantation loss than that of Group I. Group III had the highest percent pre-implantation loss among those of the treatment groups. It is significantly different from that of Group II but not from that of Group IV (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Percent pre-implantation loss among groups. Values are given as mean ± SEM. Values with the same letters are not significantly different. Group I (Unsupplemented group), Group II (Pregestation only group), Group III (Pregestation-to-gestation group), and Group IV (Gestation only group)

The percent post-implantation loss that was assessed from the implantation sites in the uteri which were classified as viable fetuses, non-viable fetuses, and resorbed embryos (Figs. [8](#Fig8){ref-type="fig"}, [9](#Fig9){ref-type="fig"}, [10](#Fig10){ref-type="fig"} and [9](#Fig9){ref-type="fig"}, respectively) showed no significant differences among all groups (Fig. [11](#Fig11){ref-type="fig"}).Fig. 8Photographs of 16.5 dpc murine uterine horns with 100% viable fetuses (*arrows*). **a** Unsupplemented group, **b** Pregestation only group, **c** Pregestation-to-gestation group, **d** Gestation only group Fig. 9Photographs of 16.5 dpc murine uterine horns showing viable and non-viable (*arrows*) fetuses. **a** Unsupplemented group, **b** Pregestation only group, **c** Pregestation-to-gestation group, **d** Gestation only group Fig. 10Photographs of 16.5 dpc murine uterine horns showing viable fetuses and resorptions (*arrows*). **a** Unsupplemented group, **b** Pregestation only group, **c** Pregestation-to-gestation group, **d** Gestation only group Fig. 11Percent post-implantation loss among groups. Values are given as mean ± SEM. Values with the same letters are not significantly different. Group I (Unsupplemented group), Group II (Pregestation only group), Group III (Pregestation-to-gestation group), and Group IV (Gestation only group)

Discussion {#Sec14}
==========

The results of the blastocyst morphometric measurements may indicate that selenium-supplementation at varying stages of periconception has not strongly influenced these morphological parameters. It appears however, that a longer period of supplementation (25 days for Group III) may have a tendency towards yielding smaller-sized blastocysts. These selected morphometric parameters are variables that seems to be not sensitive to the effects of varying the stages of maternal selenium-supplementation.

The highest percent occurrence of good quality blastocysts, that is, the lowest number of poor quality blastocysts in Group IV may indicate that the best periconception stage for selenium-supplementation to ensure good quality blastocysts is during gestation stage. It must be taken into consideration however, that percent occurrence in Group II, is high as well relative to Group III and Group I. Thus, selenium-supplementation either during pregestation only or gestation only may have similar influence on yielding good quality blastocysts. This is further supported by the abovementioned smaller-sized embryos in Group III (Table [1](#Tab1){ref-type="table"}), which is also the group that has the lowest percent occurrence of good quality blastocysts among all treatment groups.

Probably, the antioxidant system during these stages of periconception could have been enhanced by selenium-supplementation. The enhancement of antioxidant system can mitigate oxidative stress that increases during pregnancy because of an upsurge in maternal metabolic demand for energy production \[[@CR30], [@CR31]\]. Pregnancy leads to reactive oxygen species (ROS) formation that once it reached excessive levels causes detrimental effects on normal cellular functions \[[@CR10], [@CR30]\]. Based on many other studies, excessive ROS is damaging on normal female reproduction, specifically on embryo development \[[@CR10], [@CR32]--[@CR34]\].

During selenium-supplementation, this micronutrient is incorporated in the selenocysteine of antioxidative selenoproteins that include isoforms of glutathione peroxidases (GPXs) and thioredoxin reductases (TrxRs), selenoprotein P and selenoprotein W \[[@CR3]--[@CR6], [@CR8], [@CR35]\]. Selenium-supplementation during pregestation only or gestation only could have embryoprotective capacity on the deleterious impacts and influences of ROS on the structure and function of cellular macromolecules, cell membrane and mitochondria, thus preventing abnormal and delayed embryo development \[[@CR10], [@CR36]--[@CR40]\].

The high percent occurrence of poor quality blastocysts in Group I (Unsupplemented group) may be attributed to the lower levels of antioxidants than those of the supplemented groups. Poor quality blastocysts were reported as could be due to lower levels of antioxidants \[[@CR36]\].

The low percent occurrence of good quality blastocyst in Group III possibly shows the toxic effects or ineffective influence of long-term selenium supplementation. Selenium has many beneficial effects to animal and human health, but this trace mineral still has reported cases of toxicity \[[@CR3], [@CR6], [@CR41], [@CR42]\], when given in high dose \[[@CR43]\] or in long-duration \[[@CR44], [@CR45]\]. Taking into consideration that the selenium dose used in this study is at a level established to have a protective effect based from Soudani et al., \[[@CR18]\], the 25 days (pregestation-to-gestation) of selenium-supplementation might have caused a certain level of toxicity.

It was reported that long-term selenium-supplementation does not result to the optimal levels and actions of selenoproteins, but led to the overexpression of these antioxidant proteins resulting further to the development of insulin resistance, hyperglycemia, and hyperinsulinemia \[[@CR5], [@CR45], [@CR46]\]. Specifically, the overexpression of glutathione peroxidase 1 has undesirable effects to insulin- induced signaling pathways consequently promoting type 2 diabetes mellitus \[[@CR46]\]. Thus, when this metabolic disorder occurs during pregnancy, ROS is produced \[[@CR3]\], therefore risking the normal development of blastocysts.

Long-term selenium-supplementation could also affect the metabolic clearance rate of selenium, which is also influenced by the type of selenium supplement that is administered. Selenium-enriched yeast, the form of selenium supplement used in this study, is highly rich in selenomethionine (SeMet) \[[@CR47], [@CR48]\]. Reports show that SeMet is highly absorbed in the small intestine through methionine transporter system, and highly retained and accumulated in the organs \[[@CR48]--[@CR51]\] such as skeletal muscles, kidneys, liver, and pancreas \[[@CR3], [@CR49]\]. The SeMet received by female mice from selenium-enriched yeast in this study, could have lowered the excretion or the metabolic clearance rate of selenium. Further, it might have been intensified by the long-term selenium-supplementation for 25 days (pregestation-to-gestation). As a consequence, the accumulated selenium levels in the organs contributed by the organic selenium form and the selenium levels contributed by the prolonged supplementation may possibly induce embryotoxic effects to pre-implantation stage embryos, specifically to blastocysts.

The maternal selenium level damaging to blastocyst development possibly enhanced by lower metabolic clearance rate is not caused by the decline in renal hemodynamics that occurs only during the last stages of pregnancy \[[@CR52], [@CR53]\]. In fact, early stages of pregnancy are described with an increase in glomerular filtration rate and renal hemodynamic flow \[[@CR50], [@CR54]\]. Therefore, the possible lower excretion rate of selenium in female mice in this study might be an effect on the use of organic selenium supplement aggravated by long-term selenium supplementation.

The report on the reduced ovulation and implantation, and few live fetuses in rats injected intraperitoneally with high dose of sodium selenite (4.0 mg/kg body weight) \[[@CR55]\] supports the findings of this study that selenium beyond the desired status in the maternal body could have detrimental effects to embryonic development.

Pre-implantation status was also evidently supported by selenium-supplementation in Group II. Considering that Group II is not significantly different from that of Group IV, selenium-supplementation in these periconception stages could possibly lower percent pre-implantation loss. These results in pre-implantation status of Group II and Group IV are supported by the incurred high percent occurrence of good quality blastocysts (Table [2](#Tab2){ref-type="table"}) in these two periconception stages. Blastocysts with good quality have higher competency for successful implantation \[[@CR23], [@CR56]\] which is the primary determinant for successful pregnancy \[[@CR57]\].

Aside from blastocyst quality, successful implantation depends on the endometrial receptivity to the blastocyst \[[@CR56], [@CR58], [@CR59]\]. Group II having the lowest percent pre-implantation loss among groups, suggests that selenium-supplementation during pregestation only could have prepared the uterine endometrium for implantation. Since pregnancy results to a decline in glutathione peroxidase (GPx) activity \[[@CR1], [@CR3], [@CR13]\], selenium-supplementation during this periconception stage could increase the levels of glutathione peroxidase before and during the early onset of pregnancy. Specifically, the isoform of GPx involved in blastocyst implantation is glutathione peroxidase 3 (GPx3,) which was upregulated for human endometrial receptivity \[[@CR58]\], and was abnormally expressed among women who experienced implantation failure \[[@CR59]\]. Thus, selenium-supplementation during this stage can possibly prepare and improve blastocyst implantation by enhancing the level and activity of GPx3. This selenoprotein prepares the endometrium for implantation by protecting the uterine cells and embryos from excessive ROS such as hydrogen peroxides and organic hydroxyperoxides \[[@CR60]\].

Aside from GPxs, selenium-supplementation at pregestation stage and gestation stage can enhance the levels and activities of thioredoxin reductases (TrxRs), which are selenoproteins involved in reducing and maintaining the levels of small antioxidative protein known as thioredoxin \[[@CR3], [@CR6], [@CR10]\]. This reduced state protein makes developing embryos resistant from the damages of oxidative stress \[[@CR10]\] that in turn could promote association of blastocysts with the endometrial lining. The favorable results of selenium-supplementation during pregestation was supported by Kind \[[@CR61]\], which states that since poor macro- and micronutrient status of the mother before conception has tremendous impact to the establishment of pregnancy, supplementation of these nutrients before pregnancy can prepare the maternal body in supporting normal embryonic development.

The high percent pre-implantation loss in Group III, though not significantly higher than that of Group IV, but significantly higher than that of Group II strengthens the findings that selenium-supplementation during pregestation-to-gestation produces the lowest quality of blastocysts among treatment groups, which may lower the chance of successful implantation.

Conclusions {#Sec15}
===========

The overall findings of the present study indicate that pregestation only and gestation only are the best periconception stages for selenium-supplementation to yield high percent occurrence of good quality blastocysts and pre-implantation success.
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